000			01540 a2200385 4500
005			20250517224810.0
264		0	_c20200331
008			202003s 0 0 eng d
022			_a1520-5711
024	7		_a10.1080/10543406.2018.1489400 _2doi
040			_aNLM _beng _cNLM
100	1		_aHuang, Bo
245	0	0	_aQuantitative decision-making in randomized Phase II studies with a time-to-event endpoint. _h[electronic resource]
260			_bJournal of biopharmaceutical statistics _c2019
300			_a189-202 p. _bdigital
500			_aPublication Type: Journal Article
650	0	4	_aBiostatistics _xmethods
650	0	4	_aCarcinoma, Pancreatic Ductal _xdrug therapy
650	0	4	_aClinical Trials, Phase II as Topic _xstatistics & numerical data
650	0	4	_aClinical Trials, Phase III as Topic _xstatistics & numerical data
650	0	4	_aData Interpretation, Statistical
650	0	4	_aDecision Making
650	0	4	_aEndpoint Determination _xstatistics & numerical data
650	0	4	_aHumans
650	0	4	_aPancreatic Neoplasms _xdrug therapy
650	0	4	_aRandomized Controlled Trials as Topic _xstatistics & numerical data
650	0	4	_aResearch Design _xstatistics & numerical data
650	0	4	_aTime Factors
650	0	4	_aTreatment Outcome
700	1		_aTalukder, Enayet
700	1		_aHan, Lixin
700	1		_aKuan, Pei-Fen
773	0		_tJournal of biopharmaceutical statistics _gvol. 29 _gno. 1 _gp. 189-202
856	4	0	_uhttps://doi.org/10.1080/10543406.2018.1489400 _zAvailable from publisher's website
999			_c28595733 _d28595733